For patients with complex chronic wounds that have not responded to standard care, placental membrane allografts represent one of the most significant advances in wound management over the past two decades. The clinical evidence base has grown substantially, reimbursement pathways are well-established, and the products available today — including completeFT™ — offer multi-layer tissue constructs that deliver a rich biological matrix to the wound environment.
This post covers the biology of placental tissue, what the published clinical literature shows, how completeFT™ is structured and why that matters, and practical considerations for integrating it into a wound care program.
Why Placental Tissue?
The placenta has unique biological properties that make it well-suited for wound management applications. It is immunologically privileged — meaning it does not trigger a significant host immune response when applied to a wound — which allows it to be used as an allograft without the rejection concerns associated with other tissue types.
Placental tissue is rich in biological components that are relevant to wound bed biology: growth factors, cytokines, extracellular matrix proteins, and structural components that support cell migration and tissue remodeling. These are naturally present in the tissue and are preserved through the processing methods used to prepare clinical-grade allografts.
Key Biological Components
- Growth factors — including EGF, FGF, PDGF, TGF-β, and VEGF — associated with angiogenesis, fibroblast activity, and epithelialization in published research
- Extracellular matrix proteins — collagen, fibronectin, laminin — that provide structural scaffolding relevant to cell migration
- Cytokines and anti-inflammatory mediators that may modulate the wound environment and chronic inflammation
- Hyaluronic acid, which is associated with cell proliferation, migration, and moist wound environment maintenance
The completeFT™ Difference: Full-Thickness Multi-Layer Construction
Not all placental allografts are the same. Products vary significantly in their tissue composition, processing methods, and the layers of placental membrane they include. completeFT™ is a full-thickness placental membrane allograft — meaning it includes all three primary layers of the placental membrane: the Amnion, the Intermediate Layer, and the Chorion.
Amnion
The innermost layer of the placental membrane, the amnion is a thin, avascular tissue rich in growth factors and extracellular matrix proteins. It has been the most widely studied layer in wound care applications and is the primary component in many single-layer amniotic membrane products.
Intermediate Layer
The intermediate layer — sometimes called the spongy layer — sits between the amnion and chorion and contains a loose network of collagen fibers, proteoglycans, and glycoproteins. It contributes to the overall thickness and structural integrity of the graft and provides additional extracellular matrix support.
Chorion
The outermost layer of the placental membrane, the chorion is thicker and more structurally robust than the amnion. It contains a higher density of growth factors and cytokines, including factors associated with angiogenesis and inflammation modulation in published literature. Including the chorion in the construct increases the biological payload delivered to the wound bed.
Clinical Evidence
The published clinical literature on placental membrane allografts in chronic wound management is substantial and continues to grow. Key findings include:
- Randomized controlled trials reporting higher rates of wound area reduction compared to standard care in diabetic foot ulcer populations
- Prospective studies documenting reductions in wound area and depth in venous leg ulcer populations
- Retrospective analyses supporting use in pressure injuries, post-surgical wounds, and other complex wound types
- A favorable safety profile with low rates of adverse events across large patient populations
The evidence base has been sufficient to support Medicare coverage under the skin substitute benefit, with established HCPCS coding and reimbursement pathways for outpatient wound care settings.
Clinical Considerations
Placental membrane allografts are generally considered for chronic wounds that have not responded adequately to standard care. Published literature and payer coverage criteria commonly reference factors such as wound duration, wound area reduction trajectory, wound type, wound bed status, and vascular adequacy as part of the clinical evaluation process. Specific patient selection and application decisions should always be made by the treating clinician based on individual patient presentation.
Practical Application and Reimbursement
completeFT™ is applied in the outpatient wound care setting following standard wound bed preparation. The graft is sized to the wound, applied to the wound bed, and secured with a non-adherent primary dressing and appropriate secondary dressing. Application frequency and reassessment intervals are determined by the treating clinician based on wound response.
Reimbursement under Medicare Part B requires documentation of wound type, wound duration, wound measurements, prior treatment history, and the clinical rationale for advanced wound care. Nu Endeavors provides documentation templates and coding support to help wound care centers capture appropriate reimbursement and reduce claim denial risk.
This content is intended for informational and educational purposes only and does not constitute medical advice. Product selection and clinical application should be guided by a qualified healthcare provider based on individual patient presentation and clinical judgment.